Posted by Michael Wonder on 28 Jan 2022
Pfizer's COVID-19 vaccine (Comirnaty) provisionally approved for use as a booster in individuals aged 16-17 years old
28 January 2022 - The Therapeutic Goods Administration has provisionally approved the Pfizer COVID-19 vaccine, Comirnaty for use as a booster in individuals aged 16 and 17 years old.
This decision follows the provisional approval granted by the TGA to Pfizer for the use of Comirnaty as a booster in individuals 18 years and older on 26 October 2021.
Booster doses of Comirnaty in this age group have been approved for use in the US, Israel and the UK.
